nodes	percent_of_prediction	percent_of_DWPC	metapath
Zileuton—Pharyngolaryngeal pain—Varenicline—nicotine dependence	0.072	0.0979	CcSEcCtD
Zileuton—Laryngeal pain—Varenicline—nicotine dependence	0.0714	0.097	CcSEcCtD
Zileuton—Hypertonia—Varenicline—nicotine dependence	0.0426	0.058	CcSEcCtD
Zileuton—Lymphadenopathy—Varenicline—nicotine dependence	0.0414	0.0562	CcSEcCtD
Zileuton—Sleep disorder—Varenicline—nicotine dependence	0.0408	0.0554	CcSEcCtD
Zileuton—Abdominal pain upper—Varenicline—nicotine dependence	0.0322	0.0438	CcSEcCtD
Zileuton—Conjunctivitis—Varenicline—nicotine dependence	0.0264	0.0359	CcSEcCtD
Zileuton—Sinusitis—Varenicline—nicotine dependence	0.0255	0.0347	CcSEcCtD
Zileuton—Flatulence—Varenicline—nicotine dependence	0.021	0.0285	CcSEcCtD
Zileuton—Ill-defined disorder—Varenicline—nicotine dependence	0.0197	0.0268	CcSEcCtD
Zileuton—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0193	0.0728	CbGpPWpGaD
Zileuton—Malaise—Varenicline—nicotine dependence	0.0192	0.0261	CcSEcCtD
Zileuton—Chest pain—Varenicline—nicotine dependence	0.0181	0.0246	CcSEcCtD
Zileuton—Myalgia—Varenicline—nicotine dependence	0.0181	0.0246	CcSEcCtD
Zileuton—Arthralgia—Varenicline—nicotine dependence	0.0181	0.0246	CcSEcCtD
Zileuton—Discomfort—Varenicline—nicotine dependence	0.0179	0.0243	CcSEcCtD
Zileuton—EPHX2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0179	0.0675	CbGpPWpGaD
Zileuton—EPHX2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0166	0.0628	CbGpPWpGaD
Zileuton—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0158	0.0215	CcSEcCtD
Zileuton—Insomnia—Varenicline—nicotine dependence	0.0157	0.0213	CcSEcCtD
Zileuton—Somnolence—Varenicline—nicotine dependence	0.0154	0.021	CcSEcCtD
Zileuton—Dyspepsia—Varenicline—nicotine dependence	0.0153	0.0208	CcSEcCtD
Zileuton—Gastrointestinal disorder—Varenicline—nicotine dependence	0.015	0.0204	CcSEcCtD
Zileuton—Constipation—Varenicline—nicotine dependence	0.0148	0.0202	CcSEcCtD
Zileuton—Pain—Varenicline—nicotine dependence	0.0148	0.0202	CcSEcCtD
Zileuton—Feeling abnormal—Varenicline—nicotine dependence	0.0143	0.0194	CcSEcCtD
Zileuton—Urticaria—Varenicline—nicotine dependence	0.0138	0.0187	CcSEcCtD
Zileuton—Body temperature increased—Varenicline—nicotine dependence	0.0137	0.0186	CcSEcCtD
Zileuton—Hypersensitivity—Varenicline—nicotine dependence	0.0128	0.0174	CcSEcCtD
Zileuton—LTB4R—GPCR ligand binding—TAS2R16—nicotine dependence	0.0123	0.0466	CbGpPWpGaD
Zileuton—Pruritus—Varenicline—nicotine dependence	0.0123	0.0167	CcSEcCtD
Zileuton—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.0119	0.0451	CbGpPWpGaD
Zileuton—Diarrhoea—Varenicline—nicotine dependence	0.0119	0.0161	CcSEcCtD
Zileuton—Dizziness—Varenicline—nicotine dependence	0.0115	0.0156	CcSEcCtD
Zileuton—Vomiting—Varenicline—nicotine dependence	0.011	0.015	CcSEcCtD
Zileuton—Rash—Varenicline—nicotine dependence	0.0109	0.0149	CcSEcCtD
Zileuton—Dermatitis—Varenicline—nicotine dependence	0.0109	0.0149	CcSEcCtD
Zileuton—Headache—Varenicline—nicotine dependence	0.0109	0.0148	CcSEcCtD
Zileuton—Nausea—Varenicline—nicotine dependence	0.0103	0.014	CcSEcCtD
Zileuton—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.0102	0.0386	CbGpPWpGaD
Zileuton—LTB4R—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00796	0.0301	CbGpPWpGaD
Zileuton—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00787	0.0298	CbGpPWpGaD
Zileuton—PTGS1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00764	0.0289	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00696	0.0263	CbGpPWpGaD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00682	0.0258	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—TAS2R16—nicotine dependence	0.00632	0.0239	CbGpPWpGaD
Zileuton—LTB4R—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00575	0.0218	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—FGD1—nicotine dependence	0.00546	0.0207	CbGpPWpGaD
Zileuton—UGT1A9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00528	0.02	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—OPRM1—nicotine dependence	0.00519	0.0196	CbGpPWpGaD
Zileuton—UGT1A9—Biological oxidations—CYP2A7—nicotine dependence	0.00498	0.0188	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—FGD1—nicotine dependence	0.00496	0.0188	CbGpPWpGaD
Zileuton—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00496	0.0187	CbGpPWpGaD
Zileuton—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00493	0.0187	CbGpPWpGaD
Zileuton—UGT1A9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00491	0.0186	CbGpPWpGaD
Zileuton—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00489	0.0185	CbGpPWpGaD
Zileuton—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00423	0.016	CbGpPWpGaD
Zileuton—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00418	0.0158	CbGpPWpGaD
Zileuton—PTGS1—Biological oxidations—CYP2A7—nicotine dependence	0.00406	0.0154	CbGpPWpGaD
Zileuton—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00402	0.0152	CbGpPWpGaD
Zileuton—LTB4R—GPCR ligand binding—DRD2—nicotine dependence	0.00375	0.0142	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TAS2R16—nicotine dependence	0.00373	0.0141	CbGpPWpGaD
Zileuton—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00343	0.013	CbGpPWpGaD
Zileuton—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00327	0.0124	CbGpPWpGaD
Zileuton—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00323	0.0122	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—OPRM1—nicotine dependence	0.00293	0.0111	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—FGD1—nicotine dependence	0.00293	0.0111	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—CYP2A7—nicotine dependence	0.00288	0.0109	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—OPRM1—nicotine dependence	0.00267	0.0101	CbGpPWpGaD
Zileuton—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00265	0.01	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—AKR1B10—nicotine dependence	0.00259	0.00979	CbGpPWpGaD
Zileuton—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00226	0.00856	CbGpPWpGaD
Zileuton—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00213	0.00807	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—DRD2—nicotine dependence	0.00212	0.00803	CbGpPWpGaD
Zileuton—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0021	0.00796	CbGpPWpGaD
Zileuton—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00193	0.00732	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—DRD2—nicotine dependence	0.00193	0.00729	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—WASF2—nicotine dependence	0.00182	0.0069	CbGpPWpGaD
Zileuton—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00182	0.0069	CbGpPWpGaD
Zileuton—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0018	0.0068	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—WASF1—nicotine dependence	0.00175	0.00662	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CYP2A7—nicotine dependence	0.0016	0.00606	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—OPRM1—nicotine dependence	0.00157	0.00596	CbGpPWpGaD
Zileuton—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00149	0.00565	CbGpPWpGaD
Zileuton—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.00141	0.00532	CbGpPWpGaD
Zileuton—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00139	0.00525	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—DRD2—nicotine dependence	0.00114	0.00431	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CYP2A7—nicotine dependence	0.000852	0.00322	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CYP2A7—nicotine dependence	0.000694	0.00263	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000365	0.00138	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000312	0.00118	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000241	0.000911	CbGpPWpGaD
